title: Characterization of site I on human serum albumin: concept about the structure of a drug binding site.
abstract: Human serum albumin (HSA) possesses at least three sites or areas for high-affinity binding of drugs. Of these sites, site I was investigated by series of ultrafiltration and equilibrium dialysis experiments. Three ligands, acenocoumarol, dansyl-L-asparagine (DNSA) and n-butyl p-aminobenzoate (n-butyl p-ABE) were employed as marker ligands. Each ligand binds to a single high-affinity site on HSA, and binding studies with different pairs of the ligands revealed independent high-affinity binding. Preliminary displacement studies performed with the typical site I binding drugs warfarin, phenylbutazone and iodipamide showed different displacement patterns of the three marker ligands. These studies were followed by stringent competition experiments involving all possible combinations of the three test ligands themselves and of these and the three marker ligands. On the basis of the results obtained it seems that the acenocoumarol and DNSA binding regions correspond to the warfarin and azapropazone binding regions, respectively, of site I reported by others (Fehske, Schläfer, Wollert and Müller (1982) Mol. Pharmacol. 21, 387-393). The new binding region, represented by n-butyl p-ABE, is probably located adjacent to the acenocoumarol binding region but apart from that of DNSA. We have elaborated a model for binding site I in which we propose novel nomenclatures, region Ia, Ib, and Ic for the acenocoumarol, DNSA and n-butyl p-ABE binding regions, respectively. Furthermore, the relation between these regions and the high-affinity binding sites for other drugs have been discussed.
authors.affiliation: Faculty of Pharmaceutical Sciences, Kumamoto University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Yamasaki
authors.forename: T
authors.initials: T
authors.lastname: Maruyama
authors.forename: U
authors.initials: U
authors.lastname: Kragh-Hansen
authors.forename: M
authors.initials: M
authors.lastname: Otagiri
mesh_terms: D000074:Acenocoumarol / Q000378:metabolism; D000925:Anticoagulants / Q000378:metabolism; D001216:Asparagine / Q000031:analogs & derivatives / Q000378:metabolism; D001566:Benzocaine / Q000031:analogs & derivatives / Q000378:metabolism; D001665:Binding Sites; D001667:Binding, Competitive; D003619:Dansyl Compounds / Q000378:metabolism; D005456:Fluorescent Dyes / Q000378:metabolism; D006801:Humans; D007458:Iodipamide / Q000378:metabolism; D010653:Phenylbutazone / Q000378:metabolism; D012709:Serum Albumin / Q000737:chemistry* / Q000378:metabolism; D014859:Warfarin / Q000378:metabolism
chemical_list: D000925:Anticoagulants; D003619:Dansyl Compounds; D005456:Fluorescent Dyes; D012709:Serum Albumin; C031592:dansyl asparagine; D014859:Warfarin; D001216:Asparagine; C004605:butamben; D010653:Phenylbutazone; D000074:Acenocoumarol; D007458:Iodipamide; D001566:Benzocaine